RECENT ANIMAL TESTING WITH PFC'S
The first formal report of recent animal testing of our liquid ventilation product, Fluorovent, was presented at the
1995 Hot Topics in Neonatology Conference
that was attended by more than 1,000 physicians and scientists from around the world.
Fluorovent, made with new fluorocarbon, has a much slower evaporation rate than was previously achievable. This is considered an important selection criteria for a beneficial liquid ventilation product and relates to safety and cost-effectiveness. In addition, Fluorovent did not cause hyperinflated lung syndrome, a toxic side-effect experienced by different fluorocarbons (PFCs). Our studies show that SYBD has developed an improved safer, cost-effective liquid ventilation product. Further animal testing is justified.
Dr. Thomas Shaffer, a leading researcher in liquid ventilation, led the liquid ventilation section of the
Hot Topics Conference.
He noted that early research by Leland C. Clark, Jr. PhD., our Director of Research, was the genesis for today's continuing pursuit of the best PFC for liquid ventilation. Shaffer stated that PFCs have different properties, making some more suitable than others for specific clinical applications. He predicted that future research would match specific applications to "designer PFCs."
The only other liquid ventilation product currently under development, LiquiVent (Alliance Pharmaceuticals), has shown some promising results in early clinical testing, but requires continual loading and replacement dosing regimens because of its high evaporation rate, which we believe will increase treatment costs.
Stringent bioanalytical controls have made our most recent advances possible. Manufactured specifically for SYBD, Fluorovent is subject to the very highest standards of quality and purity. It is the first fluorocarbon liquid designed and developed for a specific area of critical care medicine. Other PFCs (Decalin-Green Cross of Japan and PFOB-Alliance) were originally made for commercial uses and later adapted for medicine.
SYBD has filed patent applications and others are being prepared, all having to do with the use of our new fluorocarbon liquid which will be used to treat various lung diseases including infant and adult respiratory distress, both chronic and acute. |
